FDA Grants Early Access to Promising Pancreatic Cancer Drug Daraxonrasib

goodinfo.net — Sat, 02 May 2026 07:30:00 +0800

The U.S. Food and Drug Administration (FDA) has approved an Expanded Access Program for daraxonrasib, an innovative pancreatic cancer drug developed by Revolution Medicines. The decision allows patients who are not eligible for clinical trials to access the treatment ahead of formal approval, marking a significant breakthrough in pancreatic cancer therapy.

Drug Background

Daraxonrasib is a selective inhibitor targeting the KRAS G12D mutation, developed by Revolution Medicines. KRAS gene mutations are one of the most common drivers of pancreatic cancer, accounting for approximately 35% to 40% of cases. For decades, KRAS mutations were considered “undruggable,” but recent technological advances have made it possible to selectively target specific KRAS mutations.

Clinical Trial Data

In early-stage clinical trials, daraxonrasib has demonstrated encouraging efficacy data. Some patients experienced significant tumor shrinkage, with disease control rates surpassing existing standard-of-care treatments. Perhaps most importantly, the drug has shown a favorable tolerability profile, with manageable side effects.

According to The New York Times, former U.S. Senator Ben Sasse is among the beneficiaries of the drug. After being diagnosed with pancreatic cancer, Sasse participated in the clinical trial and has seen his condition effectively controlled.

Expanded Access Program

The FDA’s approval of the Expanded Access Program, also known as “compassionate use,” allows patients with serious or life-threatening conditions to access investigational drugs before they receive formal approval.

This mechanism is particularly important for patients who are ineligible for ongoing clinical trials and have no other effective treatment options. Pancreatic cancer, often called the “king of cancers,” has a five-year survival rate of only about 12%, making it one of the cancer types with the most urgent need for new therapies.

Industry Significance

Analysts note that daraxonrasib’s progress is significant not only for pancreatic cancer patients but also opens new possibilities for treating other KRAS-mutated solid tumors, including colorectal cancer and non-small cell lung cancer.

Revolution Medicines’ shares rose following the announcement, reflecting market optimism about the drug’s commercial prospects. If daraxonrasib ultimately receives full FDA approval, it would represent a major milestone in pancreatic cancer treatment.

Next Steps

Revolution Medicines plans to continue advancing daraxonrasib through Phase III clinical trials to gather more comprehensive efficacy and safety data in support of full marketing approval. The company expects to report interim results from the pivotal trial within the next year.